{
    "clinical_study": {
        "@rank": "57141", 
        "arm_group": [
            {
                "arm_group_label": "LY2835219 + Letrozole", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 orally every 12 hours in combination with letrozole 2.5 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Anastrozole", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 orally every 12 hours in combination with anastrozole 1 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Tamoxifen", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 orally every 12 hrs in combination with tamoxifen 20 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 + Exemestane", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 orally every 12 hours in combination with exemestane 25 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 Dose #1 + Exemestane + Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 dose # 1 orally every 12 hours in combination with exemestane 25 mg and everolimus 5 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }, 
            {
                "arm_group_label": "LY2835219 Dose #2 + Exemestane + Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "LY2835219 dose #2 orally every 12 hours in combination with exemestane 25 mg  and everolimus 5 mg orally once daily in 28 day cycles.  Participants may remain on treatment until discontinuation criteria are met."
            }
        ], 
        "brief_summary": {
            "textblock": "The main purpose of this study is to evaluate the safety of a study drug known as LY2835219\n      in combination with different standard hormone therapies (letrozole, anastrozole, tamoxifen,\n      exemestane, or exemestane plus everolimus) for  hormone positive breast cancer that has\n      spread to other parts of the body."
        }, 
        "brief_title": "A Study of LY2835219 in Combination With Hormone Therapies for Breast Cancer That Has Spread", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of hormone receptor positive (HR+), human epidermal growth factor\n             receptor 2 (HER2) negative breast cancer.\n\n          -  For Part A (LY2835219 + letrozole): Except for ongoing therapy with letrozole, the\n             participant must not have received prior systemic endocrine therapy for metastatic\n             disease.\n\n          -  For Part B (LY2835219 + anastrozole): Except for ongoing therapy with anastrozole,\n             the participant must not have received prior systemic endocrine therapy for\n             metastatic disease.\n\n          -  For Part C (LY2835219 + tamoxifen): The participant may have received prior systemic\n             endocrine therapy for metastatic disease and may be receiving ongoing therapy with\n             tamoxifen.\n\n          -  For Part D (LY2835219 + exemestane): The participant must have received prior\n             systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor\n             (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy\n             with exemestane.\n\n          -  For Part E (LY2835219 + exemestane + everolimus): The participant must have received\n             prior systemic endocrine therapy with at least one nonsteroidal aromatase inhibitor\n             (anastrozole, letrozole) for metastatic disease and may be receiving ongoing therapy\n             with either exemestane or exemestane + everolimus.\n\n          -  Have either measureable disease or nonmeasureable but evaluable bone disease as\n             defined by the Response Evaluation Criteria in Solid Tumors (RECIST 1.1)\n\n          -  Participants must have either post-menopausal status or pre-menopausal status if\n             continuing or beginning ovarian suppression with a luteinizing hormone-releasing\n             hormone (LHRH) agonist such as goserelin.\n\n          -  Have adequate organ function, including:\n\n               -  Hematologic: Absolute neutrophil count (ANC) \u22651.5 x 10^9/liter (L), platelets \u2265\n                  100 x 10^9/L, and hemoglobin \u2265 8 gram/deciliter (g/dL).\n\n               -  Hepatic: Bilirubin \u22641.5 times upper limits of normal (ULN), alanine\n                  aminotransferase (ALT) \u2264 3.0 times ULN.\n\n               -  Renal: Serum creatinine \u2264 1.5 times ULN.\n\n          -  Have a performance status of \u22641 on the Eastern Cooperative Oncology Group (ECOG)\n             scale.\n\n          -  Have discontinued all previous therapies for breast cancer (including chemotherapy,\n             radiotherapy, immunotherapy, and investigational therapy), except for ongoing\n             endocrine therapy, for at least 21 days for myelosuppressive agents or 14 days for\n             nonmyelosuppressive agents prior to receiving study drug(s), and recovered from the\n             acute effects of therapy (until the toxicity resolves to either baseline or at least\n             Grade 1) except for residual alopecia or peripheral neuropathy.\n\n        Exclusion Criteria:\n\n          -  Have metastatic breast cancer with severe organ dysfunction as assessed by symptoms\n             and signs, laboratory studies, and rapid progression of the disease.\n\n          -  Have brain metastasis without prior radiotherapy.\n\n          -  Have received prior systemic chemotherapy for metastatic disease. However, the\n             participant may have received prior systemic chemotherapy in the neoadjuvant or\n             adjuvant setting.\n\n          -  Have initiated bisphosphonates or approved receptor activator of nuclear factor\n             kappa-B (RANK-L) targeted agents (for example, denosumab) \u226428 days prior to Day 1 of\n             Cycle 1.\n\n          -  Have serious preexisting medical conditions that, in the judgment of the\n             investigator, would preclude participation in this study (for example, history of\n             major surgical resection involving the stomach or small bowel).\n\n          -  Have central nervous system (CNS) metastasis and either radiotherapy or development\n             of neurological changes \u226414 days prior to receiving study treatment. Participants may\n             be receiving a stable dose of corticosteroids. Screening of asymptomatic participants\n             without history of CNS metastasis is not required."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "81", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057133", 
            "org_study_id": "15252", 
            "secondary_id": "I3Y-MC-JPBH"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LY2835219 + Letrozole", 
                    "LY2835219 + Anastrozole", 
                    "LY2835219 + Tamoxifen", 
                    "LY2835219 + Exemestane", 
                    "LY2835219 Dose #1 + Exemestane + Everolimus", 
                    "LY2835219 Dose #2 + Exemestane + Everolimus"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "LY2835219", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2835219 + Letrozole", 
                "description": "Administered orally.", 
                "intervention_name": "Letrozole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2835219 + Anastrozole", 
                "description": "Administered orally.", 
                "intervention_name": "Anastrozole", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY2835219 + Tamoxifen", 
                "description": "Administered orally.", 
                "intervention_name": "Tamoxifen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY2835219 + Exemestane", 
                    "LY2835219 Dose #1 + Exemestane + Everolimus", 
                    "LY2835219 Dose #2 + Exemestane + Everolimus"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "Exemestane", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "LY2835219 Dose #1 + Exemestane + Everolimus", 
                    "LY2835219 Dose #2 + Exemestane + Everolimus"
                ], 
                "description": "Administered orally.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Anastrozole", 
                "Exemestane", 
                "Letrozole", 
                "Sirolimus", 
                "Everolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Fayetteville", 
                        "country": "United States", 
                        "state": "Arkansas", 
                        "zip": "72703"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92037"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sarasota", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "34232"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89169"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27599"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Oklahoma City", 
                        "country": "United States", 
                        "state": "Oklahoma", 
                        "zip": "73104"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97213"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "15213"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29605"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37232"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75246"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78229"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "The Woodlands", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77380"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tyler", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75702"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Norfolk", 
                        "country": "United States", 
                        "state": "Virginia", 
                        "zip": "23502"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "6", 
        "official_title": "A Phase 1b Study of LY2835219 in Combination With Endocrine Therapies for Patients With Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Drug-Related Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline through study completion (estimated as 12 months)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057133"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, and Everolimus", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1 - Day 1:  Predose through 10 hours post dose and Day 15:  Predose.  Cycle 2 -  Day 1:  Predose through 10 hours post dose"
            }, 
            {
                "measure": "Number of Participants with a Complete or Partial Tumor Response (Overall Response Rate)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to study completion (estimated as 12 months)"
            }, 
            {
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "First dose to measured progressive disease or death of any cause (estimated as 12 months)"
            }, 
            {
                "measure": "Change from Baseline to Cycle 3 in MD Anderson Symptom Inventory (MDASI) Score", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Cycle 3"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the Curve (AUC) of LY2835219, Letrozole, Anastrozole, Tamoxifen, Exemestane, and Everolimus", 
                "safety_issue": "No", 
                "time_frame": "Cycle 1: Day 1 Predose through 10 hours post dose and Day 15 Predose.  Cycle 2:  Day 1 Predose through 10 hours post dose."
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}